Belvarafenib (developed by Hanmi Pharmaceuticals and Genentech) is a small molecule RAF dimer (type II) inhibitor[1] which shows anti-tumor clinical activity in cancer patients with BRAFV600E- and NRAS- mutations.[2]
![]() | |
Clinical data | |
---|---|
Other names | HM95573
GDC5573 RG6185 |
Routes of administration | By mouth |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C23H16ClFN6OS |
Molar mass | 478.93 g·mol−1 |
3D model (JSmol) | |
| |
|
References
edit- ^ Awada G, Neyns B (March 2022). "Melanoma with genetic alterations beyond the BRAFV600 mutation: management and new insights". Current Opinion in Oncology. 34 (2): 115–122. doi:10.1097/CCO.0000000000000817. PMID 35050937.
- ^ Kim TW, Lee J, Shin SJ, Kim JS, Kim YJ, Han HS, Lee SJ, Lim HS, Hong YH, Noh YS, Kyoung Y (31 May 2019). "Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study". Journal of Clinical Oncology. 37 (15 suppl): 3000. doi:10.1200/JCO.2019.37.15_suppl.3000.